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Group B Streptococcus Engages an Inhibitory Siglec
through Sialic Acid Mimicry to Blunt Innate Immune and
Inflammatory Responses In Vivo
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Abstract
Group B Streptococcus (GBS) is a common agent of bacterial sepsis and meningitis in newborns. The GBS surface capsule
contains sialic acids (Sia) that engage Sia-binding immunoglobulin-like lectins (Siglecs) on leukocytes. Here we use mice
lacking Siglec-E, an inhibitory Siglec of myelomonocytic cells, to study the significance of GBS Siglec engagement during in
vivo infection. We found GBS bound to Siglec-E in a Sia-specific fashion to blunt NF-kB and MAPK activation. As a
consequence, Siglec-E-deficient macrophages had enhanced pro-inflammatory cytokine secretion, phagocytosis and
bactericidal activity against the pathogen. Following pulmonary or low-dose intravenous GBS challenge, Siglec-E KO mice
produced more pro-inflammatory cytokines and exhibited reduced GBS invasion of the central nervous system. In contrast,
upon high dose lethal challenges, cytokine storm in Siglec-E KO mice was associated with accelerated mortality. We
conclude that GBS Sia mimicry influences host innate immune and inflammatory responses in vivo through engagement of
an inhibitory Siglec, with the ultimate outcome of the host response varying depending upon the site, stage and magnitude
of infection.
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Introduction
Group B Streptococcus (GBS, S. agalactiae) is a Gram-positive
encapsulated bacterium colonizing the vagina of 15–30% of healthy
women. GBS is a leading cause of neonatal pneumonia, septicemia,
and meningitis [1,2,3], and GBS colonization during pregnancy
increases the incidence of preterm rupture of membranes and
premature delivery [4,5]. A decrease in the incidence of early-onset
GBS disease in many developed countries has occurred following
implementation of universal antenatal culture screening and use of
intrapartum antibiotic prophylaxis (IAP) [6]. In contrast, the use of
IAP has not had a similar impact on the incidence of late-onset
disease, which now represents approximately one-third of total cases
[6]. Up to 50% of late-onset GBS cases develop meningitis, which
carries a very high incidence of neurocognitive sequelae – among
survivors 13% had severe, 17% moderate and 18% mild disability
at 5 years [7].
A systematic review of incidence data since 2000 estimated
an overall incidence of GBS infection in infants less than 3 months
of age of 0.53 cases per 1,000 births in the European region and
0.67 cases per 1,000 births in the Americas [8]. Less developed
countries reporting no IAP use have an overall a 2.2-fold higher
incidence of early-onset infection compared with those reporting
any use. Overall case fatality rates are approximately 7–10% in
this recent meta-analysis [8]. Of concern, the emergence of
antibiotic-resistant GBS strains has been recently reported,
likely a consequence of widespread administration of IAP
[1,9,10]. Moreover, invasive GBS infections occurring in non-
pregnant adult populations, especially the elderly and immune-
compromised, have been documented with increasing frequency
[11,12,13].
GBS expresses a capsular polysaccharide (CPS) that is a major
virulence factor contributing to evasion of host immune defense
mechanisms [14]. GBS CPS can be divided into ten serotypes
(Ia, Ib, II–IX), each with unique structural and antigenic features.
Nevertheless, all the GBS CPS repeating units share a critical
conserved element: a terminally capped sialic acid (Sia). Sia is
a nine-carbon backbone sugar present abundantly in the surface
glycocalyx of all mammalian cells, and in this manner GBS
decorates its surface with a common host epitope – a form of
molecular mimicry. The sialylated CPS is recognized as a critical
factor for GBS survival in vivo [15], interfering with host com-
plement system functions to block C3b deposition and limit C5a
production [16,17].
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An important facet of Sia biology is the function of Sia-binding
immunoglobulin-like lectins (Siglecs), receptors that are largely
expressed across the major leukocyte lineages to mediate im-
portant innate and adaptive immune functions [18,19,20,21]. A
major subset is the CD33-related Siglec family (CD33rSiglecs),
most of which possess a cytoplasmic domain containing both
a membrane-proximal immunoreceptor tyrosine-based inhibitory
motif (ITIM) and a membrane-distal ITIM-like motif [18,22].
Studies have shown that ITIMs can be tyrosine phosphorylated to
recruit Src homology 2 domain-containing tyrosine phosphatases
(SHP)-1 and SHP-2, and to trigger inhibitory signaling when the
corresponding receptors are cross-linked with agonist monoclonal
antibodies [23,24,25]. This suggests that the natural function of the
inhibitory CD33rSiglecs is the engagement of ubiquitous endog-
enous Sia motifs acting as ‘‘self-associated molecular patterns’’ in
the host to limit the baseline activation of leukocytes [26].
Through Sia mimicry, GBS has the potential to engage
inhibitory CD33rSiglecs and dampen leukocyte innate immune
responses, which may promote the survival of the pathogen [27].
In earlier work, we took advantage of Sia-blocking and Sia-
nonblocking monoclonal antibodies against human Siglec-9 to
provide in vitro evidence that GBS Sia-dependent engagement of
Siglec-9 could blunt neutrophil oxidative burst and extracellular
trap formation [28]. The significance of this phenomenon in the
context of in vivo infection remained unproven, in large part due
to rapid evolution of CD33rSiglecs in primates, such that the
composition of the CD33rSiglec family varies greatly between
primates and rodents. For example, while humans have eleven
CD33rSiglecs, mice only have five.
Murine Siglec-E has been broadly detected on the surface of
innate immune cells [25,29,30,31] and has been proposed to
represent the functional paralog of human Siglec-9. Very recently,
Siglec-E knockout (KO) mice have been generated and confirmed
to have an inhibitory role in leukocyte activation [31]. The
availability of these animals thus allows us to test for the first time
in vivo the pathogenic consequence of Sia molecular mimicry
on bacterial interactions with host inhibitory Siglecs. We report
that Siglec-E indeed interacts with GBS in a Sia-dependent
manner, triggering SHP-1 recruitment to its intracellular domain
and diminishing GBS-triggered myeloid cell innate immune and
inflammatory responses. Exaggerated responses to GBS challenge
in Siglec-E KO mice represented a ‘‘double-edged sword’’, limi-
ting GBS dissemination in sublethal systemic challenge, but
promoting accelerated septicemia and increased mortality upon
high-dose systemic challenge.
Results
GBS binds to murine Siglec-E in a Sia-dependent manner
Siglec-E has been shown to bind a wide range of sialylated lipid
probes that have a2,3, a2,6, or a2,8 sialyl linkages in glycan arrays
[32]. We first ascertained whether Siglec-E can specifically engage
GBS that expresses an a2,3-linked sialyllactosamine CPS. Fc
chimeras for Siglec-E and Siglec-9 were prebound to protein A-
coated plates in a high-avidity format, and FITC-labeled wild-type
(WT) GBS (serotype III strain COH-1) or its isogenic Sia-deficient
mutant (DSia) were added to the wells. The GBS WT strain but
not the GBS DSia mutant bound to Siglec-E, the proposed
functional paralog of Siglec-9, indicating that the GBS-Siglec-E
interaction is indeed Sia-dependent (Figure 1A). To confirm that
Siglec-E interaction with GBS is specific for Sia, we first examined
the surface charge of WT GBS and DSia mutant. As shown in
Figure S1A, the two strains bound positively charged poly-L-
lysine equivalently, which indicates that GBS WT and DSia
mutant have similar overall surface charge. In addition, we found
GBS lost its Siglec-E binding ability when the side chain of CPS
Sia was truncated by mild periodate treatment (Figure S1B),
further supporting that the GBS-Siglec-E interaction is Sia-
dependent.
Augmented innate immune responses of Siglec-E KO
macrophages upon GBS infection
WT GBS engaged Siglec-9 to dampen human neutrophil
activation [28]. The first question we sought to address is whether
Siglec-E KO leukocytes lacking expression of this major ITIM-
containing Siglec demonstrate increased bactericidal activity. WT
GBS was inoculated into freshly isolated whole blood of WT or
Siglec-E KO mice and bacteria colony-forming units (CFU) were
enumerated at the indicated time points. As shown in Figure 1B,
growth of GBS was better controlled in Siglec-E deficient mouse
blood than in WT mouse blood. Because Siglec-E has been
detected in bone marrow cells, neutrophils, peritoneal macro-
phages and monocyte/macrophage cell lines [25,31], we prepared
bone marrow-derived macrophages (MBDMs) to study the impact
of Siglec-E on the innate immune response to GBS infection.
In accordance with greater restriction of GBS growth in whole
blood from Siglec-E KO mice, absence of Siglec-E expression on
macrophages enhanced their phagocytic (Figure 1C and
Figure S2) and bactericidal (Figure 1D) activity. In addition,
WT GBS stimulated greater secretion of the pro-inflammatory
cytokines TNF-a (Figure 1E) and IL-6 (Figure 1F) from Siglec-E
deficient macrophages both at 6 h and 24 h post infection.
This phenomenon was Sia-dependent, as the isogenic GBS DSia
mutant and LPS triggered similar amounts of pro-inflammatory
cytokines from the WT compared to the Siglec-E KO cells
(Figure 1 E and F and Figure S3).
GBS binding to Siglec-E recruits SHP-1 and blunts
activating signaling pathways
The ITIM signaling motif can antagonize kinase-dependent
activation cascades by recruiting tyrosine phosphatases SHP-1 and
SHP-2 [33,34,35]. Siglec-E is constitutively associated with a low
level of SHP-1 in neutrophils, even in the absence of Siglec-E
Author Summary
The bacterium Group B Streptococcus (GBS) causes serious
infections such as meningitis in human newborn babies.
The surface of GBS is coated with a capsule made of sugar
molecules. Prominent among these is sialic acid (Sia), a
human-like sugar that interacts with protein receptors
called Siglecs on the surface of our white blood cells. In a
test tube, GBS Sia binding to human Siglecs can suppress
white blood cell activation, reducing their bacterial killing
abilities; however, the significance of this during actual
infection was unknown. To answer this question, we
studied mice for which a key white blood cell Siglec has
been genetically deleted. When infected with GBS, white
blood cells from the mutant mice are not shut off by the
pathogen’s Sia-containing sugar capsule. The white blood
cells from the Siglec-deficient mice are better at killing GBS
and are able to clear infection more quickly than a normal
mouse. However, if the mice are given an overwhelming
dose of GBS bacteria, exaggerated white blood activation
can trigger shock and more rapid death. These studies
show how ‘‘molecular mimicry’’ of sugar molecules in the
host can influence a bacterial pathogen’s interaction with
the immune system and the outcome of infection.
GBS Blunts Immune Responses by Siglec Engagement
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tyrosine phosphorylation [31]. We asked whether the recruit-
ment of SHP-1 to Siglec-E can be further enhanced upon encoun-
tering the Sia-expressing pathogen GBS. WT MBDMs were
incubated with or without WT GBS or the DSia mutant for
30 min, and Siglec-E was immunoprecipitated and probed for the
co-immunoprecipitation of SHP-1. A baseline level of endogenous
SHP-1 association with Siglec-E in the unstimulated MBDMs was
observed, consistent with a previous report on mouse bone
marrow cells [31]. The SHP-1 recruitment was slightly reduced in
the DSia mutant-treated cells compared to that of unstimulated
cells, which suggests the activation of the DSia mutant reduces
endogenous SHP-1 association to Siglec-E in the absence of Sia-
Siglec-E engagement. On other hand, enhanced SHP-1 recruit-
ment was observed on macrophages exposed to WT GBS where
Sia engagement occurs (Figure 1G).
Bacterial infections characteristically activate pattern recogni-
tion receptors such as Toll-like receptors (TLRs) to initiate MAP
kinase signaling cascades and NF-kB activation. We hypothesized
that activation of MAP kinase and NF-kB in response to GBS
may be increased in macrophages lacking Siglec-E-mediated inhi-
bitory signaling. Indeed, WT GBS triggered prolonged ERK
phosphorylation and IkB degradation in Siglec-E deficient macro-
phages than WT macrophages (Figure 1H) but no difference was
observed in p38 phosphorylation. Prolonged ERK phosphoryla-
tion and IkB degradation triggered in response to GBS challenge
in the Siglec-E KO macrophages was consistent with the en-
hanced secretion of inflammatory cytokines (Figure 1 E and F),
whereas the GBS DSia mutant triggered similar levels of ERK
phosphorylation and IkB degradation (Figure S4). We also
examined the expression of suppressor of cytokine signaling
(SOCS)-1 and SOCS-3 on the WT and Siglec-E KO macrophages
after GBS or LPS stimulation to exclude a potential general
signaling termination defect in the Siglec-E KO macrophages.
Similar SOCS-1 and SOCS-3 expression was observed on WT
Figure 1. Augmented bactericidal activity in bone marrow-derived macrophages from Siglec-E KO mice. (A) Wild-type Group B
Streptococcus (GBS WT) showed Sia-dependent binding to mSiglec-E. GBS DSia mutant is an isogenic mutant lacking Sia expression. Background
binding from hIgG1-immobilized wells, which served as a negative control, were subtracted from data shown. (B) Whole blood from Siglec-E KO mice
showed better control of GBS growth; results pooled from two independent experiments. Siglec-E KO macrophages showed greater phagocytic
activity (C) and bactericidal ability (D). GBS WT but not DSia mutant induced higher TNF-a (E) and IL-6 (F) secretion in macrophages from Siglec-E KO
animals. Differences between different groups were calculated by two-way ANOVA with Bonferroni posttest (A–B, D–F) or unpaired t test (C). ***
P,0.001; ** P,0.01; * P,0.05. (G) WT GBS stimulated macrophages recruited more SHP-1 to Siglec-E than GBS DSia mutant. (H) Enhanced ERK
activation and IkB degradation in Siglec-E KO macrophages after GBS stimulation. Representative data from two reproducible experiments are
shown.
doi:10.1371/journal.ppat.1003846.g001
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and Siglec-E KO macrophages after LPS and GBS stimulation,
indicating that Siglec-E deficiency does not result in a pervasive
defect in signal initiation and termination (Figure S5). Our data
suggest that Sia present in the GBS surface CPS engages Siglec-E
and induces SHP-1 recruitment to diminish MAP kinases and
NF-kB activation. This pattern of pathogen subversion of host
responses by engagement of the inhibitory Siglec was not observed
in the Siglec-E KO macrophages nor in WT macrophages
stimulated with the GBS DSia mutant.
Skewed cytokine responses in Siglec-E KO mice
challenged in a GBS intranasal pneumonia model
In an earlier study, we showed that removal of the tonic
inhibitory signals from Siglecs by cleaving their endogenous cis-
ligands with pneumococcal sialidase provokes increased leuko-
cyte inflammatory responses [36]. Since the loss of the principal
inhibitory Siglec (Siglec-E) on murine macrophages increased their
bacterial killing, ERK and NF-kB signaling, and inflammatory
cytokine release in vitro (Figure 1), we next examined whether
intranasal GBS challenge triggered exaggerated cytokine responses
in vivo. At an early time point (6 h post-infection), no significant
differences in bacteria load in lung tissues (Figure 2A) nor
infiltrated immune cells from the bronchoalveolar lavage (BAL)
(Figure 2B) were observed. However, significantly higher levels of
IL-1b (Figure 2C) and IL-6 (Figure 2D) were found in the BAL
fluid from GBS-infected Siglec-E KO mice. Moreover, a
significant decrease in secretion of the anti-inflammatory cytokine
IL-10 was observed in the lung tissue of Siglec-E KO mice after
GBS challenge (Figure 2E), consistent with a previous report that
presence of Siglec-9 on cultured THP-1 macrophages resulted in
reduced TNF-a mRNA expression accompanied with increased
IL-10 mRNA levels [37]. The elevated inflammatory cytokine
production and the decreased secretion of IL-10 in the Siglec-E
deficient mice in response to acute localized GBS infection
suggested that loss of the immunoregulatory ITIM-containing
Siglec-E in leukocytes skews the host immune response toward a
more inflammation prone set point.
Absence of Siglec-E exacerbates inflammation and
accelerates mortality in systemic lethal dose GBS
challenge
Mice lacking Siglec-G were more susceptible to intestinal
perforation-induced sepsis due to disruption of a Siglec-G/CD24
interaction, which leads to a failure in repressing host danger
signaling-mediated inflammation [38]. Reduced IL-10 secretion
together with excessive inflammatory cytokine production in
Siglec-E KO mice upon local GBS infection let us speculate that,
lacking inhibitory signals from the major Siglec expressed on
macrophages, may lead to exaggerated inflammation and septi-
cemia during high-dose systemic GBS infection. Sialylated CPS is
Figure 2. Skewed cytokine responses in Siglec-E KO mice challenged in a GBS intranasal pneumonia model. Mice were infected
intranasally with 56107 CFU WT GBS and cytokine levels in cell-free BAL fluid or lung homogenates collected 6 h post infection. (A) Bacterial load in
lung tissue was calculated by dilution plating for CFU enumeration. (B) Cells from BAL were counted and stained with mAb to F4/80 and Gr-1 to
quantitate infiltrating cell populations. IL-1b (C) and IL-6 (D) in the BAL and IL-10 in lung homogenates (E) were examined by ELISA analysis. Data
shown are means 6 SEM and each circle denotes 1 mouse (n = 8 for WT and n= 7 for mSiglec-E KO mice). The difference between different groups
was calculated by Mann-Whitney test.
doi:10.1371/journal.ppat.1003846.g002
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recognized as a critical factor for GBS survival in vivo [15,39], and
the LD50 values of CPS deficient strains are up to 10
5-fold greater
than the WT strains [15,40]; thus we are only able to model
sustained infection with WT GBS and not the DSia mutant. When
WT and Siglec-E KO mice were challenged with 36108 CFUWT
GBS intravenously, 80% of WT mice survived the observation
period whereas the majority of mice lacking Siglec-E died within
48 h (Figure 3A). In parallel with reduced survival rates in Siglec-
E KO animals, serum levels of IL-6 (Figure 3B) and acute phase
protein, serum amyloid A (SAA) (Figure 3C) 18 h after infection
were substantially higher in Siglec-E KO animals relative to WT
controls. The increased mortality of Siglec-E KO mice was not
attributable to differences in bacterial burden in the animals, since
similar GBS CFU were recovered from the blood (Figure 3D)
and brains (Figure 3E) of WT and Siglec-E KO mice. These
results suggested that the accelerated fatality in Siglec-E KO mice
upon high dose GBS challenge involved impaired regulation of
inflammatory cytokine production.
Reduced brain dissemination and enhanced bactericidal
responses in Siglec-E deficient mice upon sublethal GBS
challenge
Loss of Siglec-E expression was harmful for animals upon
high-dose lethal GBS challenge due to excessive inflammation.
However, as GBS Sia CPS is known to dampen neutrophil
bactericidal activity by targeting Siglec-9 [28], we postulated
that under lower-dose challenge conditions Siglec-E KO animals
could benefit from loss of negative feedback on innate immunity
response pathways. Consequently, WT and Siglec-E KO mice
were infected with sublethal dose of GBS intravenously. GBS
counts detected in the blood 4 h post-infection in each group were
essentially identical, suggesting consistent establishment of sys-
temic infection (Figure S6A). None of the mice died within 48 h
under sublethal GBS challenge, and infected mice were eutha-
nized 48 h postinfection to assess bacterial dissemination to the
brain and other organs. Whereas no significant overall difference
in the blood GBS CFU was observed between WT and Siglec-
E deficient mice, a few Siglec-E KO mice showed complete
clearance of GBS in the blood (Figure S6B). When compared to
the WT mice, GBS-infected Siglec-E KO mice had a modest
reduction in bacterial counts in the kidney (P=0.046, Figure 4A).
Bacterial brain GBS CFU counts were also significantly lower in
Siglec-E than in WT mice (P=0.0055) (Figure 4B), as was the
ratio of CFU recovered from the brain over the bloodstream
(P=0.0178) (Figure 4C).
We further measured the cytokine production in the mice after
nonlethal GBS infection. Elevated serum IL-6 and SAA in the
GBS-infected Siglec-E deficient mice was observed 18 h postin-
fection (Figure S7A and B), although there was no difference in
blood and brain bacterial loads in WT and Siglec-E deficient mice
at the earlier infection stage (Figure S7C and D). No detectable
inflammatory cytokines (TNF-a, IL-1b and IL-12) were present in
the serum collected at the time mice were sacrificed (48 h). The
failure of cytokine detection may be due to the quick drop of
systemic serum inflammatory cytokines after infection. However,
Figure 3. Absence of Siglec-E exacerbates inflammation and accelerates mortality in a systemic lethal dose GBS challenge. WT and
Siglec-E KO mice were challenged intravenously with 36108 CFU of WT GBS. (A) Kaplan-Meier plot is shown for survival analysis (n= 10 for each
group). Blood and brains were collected 18 h after GBS infection to measure IL-6 (B), serum amyloid A (C) and bacteria loads (D and E). Data shown
are means 6 SEM and each circle denotes 1 mouse (n= 6 for WT and n= 8 for Siglec-E KO mice). Differences between different groups were
calculated by Mann-Whitney test (B–E).
doi:10.1371/journal.ppat.1003846.g003
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quantative RT-PCR analysis revealed that the GBS-infected
Siglec-E deficient mice had increased transcript levels of IL-1b and
IL-12 (Figure 4 D and E) compared to WT mice, consistent with
the findings that loss of Siglec-E expression augmented inflam-
matory cytokine production in vitro and in vivo. Corroborating what
we found in the localized intranasal pneumonia model, reduced
IL-10 transcript production in Siglec-E KO mice was observed
after low-dose GBS infection (Figure 2E and 4F). Our data show
for the first time that an ITIM-containing Siglec can promote
expression of the anti-inflammatory IL-10 in response to a
sialylated bacterial pathogen.
Contribution of microglia cells in the control of GBS brain
dissemination
We observed reduced GBS brain CFU counts in Siglec-E KO
mice after intravenous infection despite similar blood CFU counts
in WT and Siglec-E KO animals. Microglial cells are the major
resident macrophage population in the central nervous system
parenchyma and are also part of the blood-brain barrier
composition, which collectively poise them to function as a first
line of defense against invading pathogens [41,42,43]. Since
macrophages lacking Siglec-E expression exhibited greater bacte-
ricidal activity and inflammatory cytokine production, important
for the control the growth and dissemination of bacteria, we tested
whether microglia cells in the Siglec-E KO mice might contribute
to reduced spread of GBS into the central nervous systems upon a
systemic GBS infection. Microglial cells derived from WT animals
showed low level expression of Siglec-E (data not shown), and loss
of Siglec-E expression on microglia cells enhanced their GBS
bactericidal activity (Figure 4G). In accordance with greater
inflammatory cytokine secretion in the Siglec-E deficient macro-
phages following WT GBS stimulation (Figure 1 E and F), WT
GBS also stimulated greater TNF-a secretion the Siglec-E KO
microglia cells 24 h post infection. Once again, the GBS DSia
mutant triggered similar amounts of TNF-a secretion in WT vs.
Siglec-E KO cells (Figure 4H).
Figure 4. Reduced brain dissemination and enhanced bactericidal responses in Siglec-E deficient mice upon sublethal GBS
challenge. Comparison of bacterial counts (expressed in CFU) recovered from the kidney (A) and brain (B) of WT mice and Siglec-E KO mice 48 h
after intravenous challenge with 16108 CFU of WT GBS. (C) Brain bacterial counts were corrected for blood contamination (brain/blood ratio) using a
conservative estimate of the mouse cerebral blood volume (2.5 ml per 100 g tissue). mRNA expression of IL-1b (D) and IL-12 (E) in lung and IL-10 in
spleen (F) was examined by quantitative real time RT-PCR analysis. Results pooled the data from two independent experiment with final numbers of
n= 14 for each group. Each circle denotes 1 mouse (A–F). Siglec-E KO microglia cells showed greater bactericidal ability (G) and produced higher
levels of TNF-a (H) after GBS challenge. Statistical analysis was performed by Mann-Whitney test (A–F), two-way ANOVA with Bonferroni posttest (G)
and one-way ANOVA with Tukey’s multiple comparison test (H). *P,0.05.
doi:10.1371/journal.ppat.1003846.g004
GBS Blunts Immune Responses by Siglec Engagement
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Discussion
In the present study, we report that GBS can engage mouse
Siglec-E, a functional paralog of human Siglec-9, and directly
address the consequence of host responses in vivo in the context of
presence or absence of this major inhibitory Siglec expressed on
the innate immune cells during live infection with a sialylated
bacterial pathogen. Loss of Siglec-E expression significantly
enhanced macrophage inflammatory and bactericidal activity
against GBS. The outcome and host survival was associated with
the magnitude of infection and infection-induced inflammatory
responses. Animals lacking Siglec-E expression appeared to benefit
by the elevated inflammatory and bactericidal responses upon a
low dose GBS infection. In contrast, the detrimental overwhelm-
ing inflammation accelerated mortality in the Siglec-E-deficient
animals followed by a lethal dose challenge.
Leukocyte activation is controlled by a sophisticated balance
between stimulatory and inhibitory signals through activating
and inhibitory receptors, respectively. Bacterial infections activate
pattern recognition receptors, such as TLRs, which to recognize
highly conserved microbial motifs to initiate MAP kinase and NF-
kB activation required for cell activation. However, the termina-
tion of such activation signals is equally critical to fine-tune the
magnitude of inflammation to mitigate host cell damage, such
that the overall response is dependent on all downstream signals
delivered by the engaged receptors. Many inhibitory receptors
contain one or more characteristic sequences (V/IXYXXL/V) in
the cytoplasmic domain classified as an ITIM. Phosphorylation
of the tyrosine residue within the ITIM allows the binding of
protein tyrosine phosphatases SHP-1 and/or SHP-2 or the
inositol phosphatase SHIP through their SH2 domains [44,
45,46]. When recruited to the complex, these phosphatases act to
block signal transduction by dephosphorylating key proteins or
lipids of a signaling cascade. Thus, regardless of the structural type
of an inhibitory receptor, the inhibitory mechanism is similar.
The molecular features and signaling properties of the ITIM-
containing CD33rSiglecs point to a potentially important role
in the limitation of excess inflammatory responses upon cell
activation [21]. Reduced CD33 surface expression on human
monocytes by RNA interference silencing or antibody blockade
resulted in the increased secretion of IL-1b, IL-8, and TNF-a [47].
On the other hand, overexpression of WT Siglec-9, but not Siglec-
9 with a mutated tyrosine into phenylalanine on the cytoplasmic
ITIM motif, led to reduced TNF-a and IL-6 production upon
TLR ligation [37]. In addition, ligation of Siglec-9 on monocyte-
derived dendritic cells by tumor-derived Sia-containing mucins or
anti-Siglec-9 antibodies suppressed IL-12 production upon LPS
stimulation [48]. Similar findings can be extended to the murine
Siglecs in that crosslinking of Siglec-E on LPS-treated macro-
phages also impaired their inflammatory cytokine production [30].
In accordance with these in vitro cell experiments, we found that
GBS engages Siglec-E in a Sia-dependent manner to recruit SHP-
1 and to influence ERK and NF-kB signaling, thereby reducing
the associated inflammatory cytokine secretion and bactericidal
activity (Figure 1). We further demonstrated that the singular loss
of the major inhibitory Siglec, Siglec-E, on innate immune cells
was sufficient to augment the inflammatory cytokine secretion
accompanied with reduced anti-inflammatory IL-10 production
during a local GBS intranasal challenge (Figure 2). This provides
the first evidence to demonstrate that a sialylated pathogen can
exploit inhibitory CD33rSiglec to negatively modulate the host
inflammatory status during an in vivo infection.
A recent report demonstrated accelerated neutrophil and
macrophage recruitment in the Siglec-E deficient lungs upon
intranasal LPS administration [31]. The authors found this
phenomenon was mediated through Siglec-E by suppression of
CD11b outside-in signaling when Siglec-E was engaged by the
sialylated CD11b ligand, fibrinogen. This Siglec-E-mediated
suppression was Sia-dependent, since asiolo-fibrinogen, LPS and
immuno-complex exposure did not alter the same downstream
signaling observed with sialylated fibrinogen. These data examin-
ing endogenous Sias on the host fibrinogen, together with our
observations regarding exogenous Sia on pathogens, emphasize
the broad significance of Sia-dependent immune cell regulation
through Siglec engagement.
Deficiency in inhibitory pathways results in profound immune
defects characterized both by decreased activation thresholds and
hyperresponsiveness phenotypes, which often lead to autoimmu-
nity and chronic inflammation [49,50,51,52]. Mice deficient
in Siglec-F displayed enhanced eosinophilic inflammation [53],
while animals lacking Siglec-G expression were more susceptible
to intestinal perforation-induced sepsis due to failure in repressing
host danger signaling-mediated inflammation [38]. In general,
a fine balance must be achieved when encountering pathogens:
sufficient innate immune responses must be generated in order to
eliminate pathogens, but the inflammatory activation must not be
too large to cause widespread host tissue damage. Upregulation
of CD33rSiglecs and/or their cognate Sia ligands may represent
a means for the host to attenuate and control inflammatory exa-
cerbation by enhancing inhibitory signaling after infection. Siglec-
E expression can be induced by pathogen associated molecular
patterns such as ligands for TLR2, 4, 7, and 9 in a MyD88-
dependent manner [30]. Reduced IL-10 secretion together with
excessive inflammatory cytokine production in Siglec-E KO
animals upon local GBS infection (Figure 2) let us evaluate
whether absence of Siglec-E expression may lead to uncontrolled
inflammation and tissue damages during a systemic lethal
challenge. Indeed, exaggerated mortality was observed on the
Siglec-E KO with higher serum IL-6 and SAA in the setting of
similar bacterial burdens (Figure 3).
Given the role of inhibitory CD33rSiglec in controlling
exaggerated inflammation, sialylated pathogens may take advan-
tage by molecular mimicry to blunt the bactericidal functions of
the immune cells in which inhibitory CD33rSiglecs are expressed
through their higher-density trans Sia ligands. We previously
reported that GBS CPS Sia mimicy allows engagement of Siglec-9
to dampen neutrophil bactericidal functions [27,28]. Here we
further demonstrate that in sublethal GBS infection, Siglec-E
deficient animals exhibited reduced bacteria dissemination and
may have benefited from the enhanced inflammatory responses
and reduced anti-inflammatory IL-10 production. Thus GBS can
trigger inhibitory signals through engaging Siglec-E to reduce
overall innate immune responses in the WT animals (Figure 4).
The established virulence function of the GBS Sia CPS is twofold,
involving interference with the complement pathway [16,17] but
also downregulation of myeloid cell innate immune activities via
engagement of inhibitory CD33rSiglecs.
CD33rSiglecs are expressed primarily on leukocyte subsets, and
whereas some are highly restricted to a certain cell type, other
CD33rSiglecs have relatively broad expression patterns. In
addition, several CD33rSiglecs can be present on the same cell
type in which they may perform a specific function or have
functional redundancy. Since the potential contribution of each
CD33rSiglec is determined primarily by its cellular expression
profile, detailed comparative analyses of the specific cell types that
express CD33rSiglecs are essential to clarify their unique roles
[18,54]. Here, we surprisingly found that in addition to the
previously known cells that express Siglec-E, such as neutrophils
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and macrophages, its expression was also present on the brain
microglia cells. Microglia cells are the major resident macrophage
population in the CNS parenchyma and part of the blood-brain
barrier (BBB) composition. The parenchymal CNS is an anti-
inflammatory environment with high local concentrations of
inflammation-suppressive cytokines such as IL-10 and TGF-b
[55,56]. Furthermore, the BBB is able to restrain CNS inflamma-
tion by excluding plasma proteins as well as peripheral immune
cells and their associated inflammatory molecules [57]. Expression
of inhibitory Siglec-11 on human microglia cells has been shown to
alleviate neurocytotoxicity [58]. Therefore, Siglec-E on microglia
may play a physiological role when encountering its endogenous cis
ligands. Although microglia are believed to function as first line of
defense against invading pathogens [41,42,43], the sialylated
GBS may suppress microglial responses by engaging Siglec-E on
microglia to facilitate the establishment of meningitis upon systemic
GBS infection. To support this hypothesis, we found that Siglec-E
KOmicroglia cells had greater microbicidal and cytokine responses
against GBS (Fig. 4 G–H) compared to WT microglia cells.
In conclusion, our data show that GBS Sia mimicry can
attenuate host innate immune responses through engagement of
an inhibitory Siglec on leukocytes, with the potential outcome on
the host response likely to vary dependent upon on the site, stage
and magnitude of infection. In localized and early-stage infection,
we propose this process can serve to diminish host macrophage
innate immune functions, promoting GBS survival and virulence.
In overwhelming infection, which could include fulminant
neonatal sepsis after ascending infection of the placental mem-
branes, engagement of GBS Sia by inhibitory CD33rSiglecs
such as Siglec-9 could ultimately act to mitigate the dysregulated
inflammatory response and cytokine storm. Similarly, microglial
Siglec-E expression could reduce inflammatory responses in the
privileged CNS compartment. A number of other invasive human
bacterial pathogens associated with meningitis, including Hae-
mophilus influenzae, Neisseria meningitidis and Escherichiae coli serotype
K1, display Sia in their CPS or cell wall lipooligosaccharides
with the potential to engage members of the CD33rSiglec family.
Further analysis of Sia-Siglec interactions during host-pathogen
encounters could provide novel targets for therapeutic intervention
to modify infectious disease outcome.
Materials and Methods
Ethics statement
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health under a
protocol approved by the Institutional Animal Care and Use
Committee at the University of California, San Diego (Animal
Welfare Assurance Number: A3033-01). All efforts were made to
minimize suffering of animals employed in this study.
Bacteria and cell lines
A well-characterized human serotype III GBS isolate (COH-1)
from a case of human neonatal sepsis was used in this study.
Generation of the isogenic DSia mutant, containing an in-frame
allelic replacement of the neuA gene encoding CMP-N-acetylneur-
aminic acid synthetase with a chloramphenicol acetyltransferase
cassette, was previously described [59]. GBS were propagated
in Todd-Hewitt broth, THB, (Difco, BD Diagnostics) at 37uC
without shaking. For infection studies, bacteria were cultivated at
37uC to mid-exponential phase and resuspended to an OD600 of
0.4, followed by serial dilution and enumeration of CFU (colony-
forming units) to verify each experimental inoculum.
Siglec-Fc binding assay
Siglec-Fc and FITC-labeled GBS interactions were performed
with slight modifications from our previously described method
[27]. To prepare FITC-labeled GBS, early exponential phase
grown GBS was pelleted, washed and then labeled with 0.1%
fluorescein isothiocyanate (FITC)/PBS for 1 h at 37uC with
rotation. Bacteria were extensively washed with PBS to remove
trace amounts of free FITC then resuspended in PBS. 96-well
plates were coated with 1 mg/well protein A in 50 mM carbonate
buffer (pH 9.5) overnight at 4uC. Wells were washed and blocked
with 1%BSA/PBS for 1 h at room temperature. Human Siglec
9-Fc, produced as previously described [60], or murine Siglec E-Fc
[29] was immobilized to individual wells for at least 3 h at room
temperature. Wells were washed three times, and 16107 FITC
labeled-GBS added to each well. Plates were centrifuged at
2000 rpm for 10 min and incubated for 30 min at 37uC. The
initial fluorescence intensity was verified, wells washed to remove
unbound bacteria, and the residual fluorescent intensity (excita-
tion, 488 nm; emission, 530 nm) measured using a CytoFluorII
fluorescent plate reader.
Culture of mouse bone marrow-derived macrophages
and in vitro stimulation
Murine bone marrow-derived macrophages were derived from
bone marrow cells collected from femur and tibia and cultured
with conditional media containing macrophage colony-stimulating
factors (M-CSF) for 7 d. For phagocytosis assays, GBS (2.56
106 CFU) were added to 56105 macrophages (multiplicity of
infection or MOI= 5), followed by incubation for 30 min or 1 h.
Cells were washed with PBS three times followed by addition
of medium containing penicillin (5 mg/ml) and gentamicin
(100 mg/ml) for 1 h to kill extracellular bacteria. Cells were then
washed, detached, and lysed with 0.025% Triton X-100 to release
intracellular bacteria. Bacterial CFU were enumerated by serial
plating on the THA plates. For bacterial killing assays, 16105 GBS
was added to macrophages (56105) at MOI= 0.2 for 1 or 2 h,
followed by addition of 50 ml of 0.6% Triton X-100 to lyse cells.
Recovered GBS were plated on THA plates for CFU enumera-
tion. Assays were performed in triplicate and were repeated three
times. To detect cytokine secretion after GBS infection, 16105
macrophages were stimulated with 106 GBS for 30 min, and then
penicillin and gentamicin added as above to prevent the bacterium
overgrowth. The culture supernatant was collected 6 h or 24 h
after GBS infection for cytokine ELISA analysis.
Culture of microglia cells and in vitro stimulation
Isolation of primary microglia cells from adult animals was
performed as previously described [61]. In brief, PBS-perfused
brains were collected and digested in an enzymatic solution
contained 116 mM NaCl, 5.4 mM KCl, 26 mM NaHCO3,
1 mM NaH2PO4, 1.5 mM CaCl2, 1 mM MgSO4, 0.5 mM
EDTA, 25 mM glucose, 1 mM cysteine and 20 units/ml papain
(all from Sigma) for 90 min at 37uC, followed by 0.5 mg/ml of
DNase I (Roche) treatment for 5 min at room temperature. The
resulted brain mixture was resuspended in 20 ml of 20% isotonic
Percoll/HBSS, carefully overlaid with 20 ml HBSS and centri-
fuged at 200 g for 20 min with slow acceleration and no brake.
The pellet containing mixed glial cells was collected, washed and
cultured in the Dulbecco’s modified Eagle’s/F12 medium with
GlutaMAX supplemented with 10% FBS, 100 units/ml penicillin,
100 mg/ml streptomycin (all from Invitrogen) and 5 ng/ml of
carrier-free murine recombinant granulocyte and macrophage
colony-stimulating factor (GM-CSF) (R&D Systems). The medium
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was changed twice a week until the cells became confluent. A
nearly pure microglial cell population was collected from the
mixed glial culture supernatant without any prior shaking and
plated in the 48-well plates (26105 cells/well) or 96-well plates
(16105 cells/well) for 3 days in medium without GM-CSF.
Bacteria killing assays and cytokine secretion after GBS infection
were performed as described above, using MOI of 0.2 for 2 h and
MOI of 10 for 24 h, respectively.
Cytokine detection
Concentrations of cytokines in macrophage supernatants
collected over time post-infection, or cytokines in mouse BAL
fluids, lung homogenates and serums from infected animals were
detected by corresponding commercial ELISA kits (TNF-a and
IL-6 from R’D; IL-1b, IL-10 and IL-12 from BD Biosciences; SAA
(serum amyloid A) from Life Diagnostics)
Immunoprecipitation and western blot analysis
Macrophages were lysed in lysis buffer (50 mM Tris, pH 8,
150 mM NaCl, 1% NP40) containing protease inhibitor cocktail
(Roche) and phosphatase inhibitor cocktail (Santa Cruz Biotech-
nology). Cell lysates were then separated on a 10% SDS-PAGE
and transferred to a PVDF membrane. The membrane was
probed with the anti-phospho p44/42 MAPK (T202/Y204), anti-
phospho p38, anti-p44/42, or anti-IkB antibodies (all from Cell
Signaling Technology), and then followed by appropriate HRP-
conjugated secondary Abs (Bio-Rad) and ECL reagent (Thermo
Scientific). Macrophages were stimulated with COH1 WT or DSia
mutant for 30 min at MOI= 10. Cells were then lysed in RIPA
buffer with protease and phosphatase inhibitor cocktail. Siglec-E
was immunoprecipitated by mouse anti-Siglec-E mAb (generated
in the Crocker lab). Immunoblots were probed with Ab to SHP-1
(Santa Cruz Biotechnology) and Siglec-E (R&D systems), respec-
tively, and then followed by appropriate HRP-conjugated
secondary Abs and ECL reagent.
Mouse infection models
All animal experiments were approved by the Committee on
the Use and Care of Animals, UCSD and performed using
accepted veterinary standards. For the murine intranasal challenge
model, mice (Siglec-E knockout mice or C57B/6 controls, 10–12
weeks) were lightly anesthetized by intraperitoneal injection of
ketamine and xylazine, and 50 ml of PBS containing 108 GBS
was then administered into the nostrils of the mice. The inoculum
dose was confirmed by viable count after plating on THA
plates. Infected animals were sacrificed 6 h post infection. Blood
was collected via terminal cardiac puncture. For bronchoalveolar
lavage (BAL) fluid collection, the trachea was exposed and 0.8 ml
PBS (without calcium and anticoagulant) was injected twice by
using an 18 guage needle connected to 1 ml syringe. Cells from
BAL were counted and stained with APC-conjugated rat anti-
mouse F4/80 mAb (AbD Serotec) and FITC-conjugated rat anti-
mouse Gr-1 mAb (Caltag Medsystems) to analyze the infiltrated
cell population after GBS infection. The left lung lobe was
collected was collected for bacterium CFU enumeration and
cytokine detection. For monitoring mouse survival after systemic
intravenous challenge, mice (10–12 weeks) were intravenously
infected with 36108 GBS and observed for 10 d. To measure
serum cytokine secretion after GBS infection, blood was collected
18 h post infection for cytokine ELISA analysis, along with
measurement of bacterial load in the blood and brain. For the
GBS meningitis model, mice (10–12 weeks) were intravenously
infected with 108 GBS and, bacteria CFU in the blood was
examined 4 h later to ensure mice received similar challenge
doses. Then 48 h after injection, samples of blood, brain/
meninges, and kidney were collected aseptically from mice after
euthanasia. Bacterial counts in blood and tissue homogenates were
determined by plating serial dilutions. Bacterial counts in brain
and kidney were corrected for differences in organ weight. Brain
bacterial counts were also corrected for blood contamination using
the blood concentration and a conservative estimate of the mouse
cerebral blood volume [62].
Real time quantitative RT-PCR
RNAs were isolated from various tissues using Trizol (Life
Technologies) and used as a template for cDNA preparation by
iScript kit (Bio-Rad). Quantitative PCR was performed using iQ
SYBR Green Supermix (Bio-Rad) according to standard proto-
cols. Primers used were for IL-1b 59-ACTACAGGCTCCGA-
GATGAAC-39 and 59-CCCAAGGCCACAGGTATTTT-39; for
IL-12, 59-CGTGCTCATGGCTGGTGCAAAG-39 and 59-
CTTCATCTGCAAGTTCTTGGGC-39; and for GAPDH, 59-
AACTTTGGCATTGTGGAAGGGC-39 and 59-GGTAGGAA-
CACGGAAGGCCATG-39. Primers for IL-10 were obtained
from QuantiTect Primer Assay (Qiagen)
Statistical analysis
Graphpad Prism version 5 was used for statistical analysis. Statistical
significance was accepted at P,0.05. Data shown were either pooled
from two independent experiments or representative data from two
independent experiments conducted with biological replicates. The
significance of differences between different groups for the animal
experiments was determined using theMann-Whitney test. Unpaired t
test, one-way ANOVA and two-way ANOVA were used for two
groups, multiple groups or two parameters comparisons, respectively.
Supporting Information
Figure S1 WT GBS and DSia mutants have similar
surface charge and expression of Sia is critical for the
GBS-Siglec-E interaction. (A) WT GBS (solid line) and DSia
mutant (dashed line) were stained with FITC-labeled poly-L-lysine
(Sigma) at 1 mg/ml for 20 min at room temperature and applied
to FACSCalibur flow cytometer. The shaded histograms are
unstained controls for each strain. (B) CFSE-labeled GBS was
treated or untreated with 2 mM NaIO4 for 20 min at 4uC in the
dark, followed by incubation with 60 mM MTSC (4-methyl-3-
thiosemicarbazide) for 60 min at 37uC. The resulting treated GBS
and DSia mutant strains were applied to Siglec-9 or Siglec-E
coated plates to test their Siglec-interacting ability. Background
binding from hIgG1-immobilized wells served as negative controls,
and was subtracted from data shown here.
(TIF)
Figure S2 Siglec-E deficient macrophages exhibit great-
er phagocytic activity against WT GBS but not GBS DSia
mutants. Mouse bone marrow-derived macrophages (MBDMs)
were incubated with pHrodo Red (Life Technologies) labeled WT
GBS or DSia mutant at 37uC for 30 min or 60 min at the MOI of
50 (A) or 5 (B). MBDMs were then washed three times with PBS
after incubation, detached using 5 mM EDTA, and applied to
FACSCalibur flow cytometer. The phagocytic activity of WT and
Siglec-E deficient MBDM was reflected by the mean fluorescence
intensity (MFI) of the cells, where the engulfed GBS exhibited red
fluorescence once inside the phagolysosome of MBDMs. Solid and
open symbols represent cells from WT and Siglec-E deficient mice,
respectively. Cells infected with WT GBS are indicated in blue
color, while cells infected with GBS DSia mutants are in green.
(TIF)
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Figure S3 Lack of Sia-Siglec-E engagement is critical for
the exaggerated cytokine secretion observed in Siglec-E-
deficient macrophages after WT GBS stimulation. Mouse
bone marrow-derived macrophages from WT or Siglec-E deficient
mice were incubated with GBS at different MOI (from 2 to 50) or
LPS at different concentrations (from 10 to 1000 ng/ml) for 24 h.
Secretion of TNF-a in the culture supernatant was determined
using a TNF-a ELISA kit.
(TIF)
Figure S4 GBS DSia mutants induce similar level of
ERK activation and IkB degradation in WT and Siglec-E
deficient macrophages. WT mouse bone marrow-derived
macrophages from WT (WT) or Siglec-E deficient (E) were treated
with GBS DSia mutants for 30 or 60 min. Cell lysates were
collected at indicated times, separated on SDS-PAGE, and probed
with antibodies recognizing phosphorylated form of ERK, total
ERK, IkB and actin.
(TIF)
Figure S5 Expression of suppressor of cytokine signal-
ing -1 (SOCS-1) and SOCS-3 in WT and Siglec-E deficient
macrophages can be detected after LPS and GBS
stimulation. Mouse bone marrow-derived macrophages
(MBDMs) were stimulated with LPS, GBS WT and GBS DSia
mutants for 24 h in the presence of antibiotics to prevent the
overgrowth of bacteria. Cell lysates were collected, separated on
SDS-PAGE, and probed with antibodies recognizing SOCS-1,
SOCS-3 and actin.
(TIF)
Figure S6 Similar blood GBS counts were observed in
the systemic GBS infection model. Comparison of bacterial
counts (expressed in CFU) recovered from the blood collected
from WT and Siglec-E deficient mice after intravenous challenge
with 108 CFU of WT GBS 4 h (A) or 48 h (B) after infection. Data
shown are means and each circle denotes 1 mouse (n=14 for each
group).
(TIF)
Figure S7 Enhanced proinflammatory cytokine secre-
tion but equivalent bacterial brain dissemination in
Siglec-E deficient mice upon sublethal GBS challenge at
an early infection time point. WT and Siglec-E KO mice
were challenged intravenously with 108 CFU of WT GBS. Blood
and brains were collected 18 h after GBS infection to measure (A)
serum IL-6 (A), (B) serum amyloid A (SAA), (C) blood and (D)
brain bacteria loads. Data shown are means 6 SEM and each
circle denotes 1 mouse (n=8 for each group). Differences between
different groups were calculated by Mann-Whitney test.
(TIF)
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